找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Experimental and Clinical Progress in Cancer Chemotherapy; Franco M. Muggia (Clinical Director) Book 1985 Martinus Nijhoff Publishers, Bos

[复制链接]
查看: 50094|回复: 42
发表于 2025-3-21 18:52:38 | 显示全部楼层 |阅读模式
书目名称Experimental and Clinical Progress in Cancer Chemotherapy
编辑Franco M. Muggia (Clinical Director)
视频video
丛书名称Cancer Treatment and Research
图书封面Titlebook: Experimental and Clinical Progress in Cancer Chemotherapy;  Franco M. Muggia (Clinical Director) Book 1985 Martinus Nijhoff Publishers, Bos
描述As in CANCER CHEMOTHERAPY 1, this volume brings to the reader highlights in three different areas of cancer therapeutics: new concepts and models; drug classes; and clinical settings. Topics were chosen because of their timeliness or probable current impact in cancer treatment. Authors were selected on the basis of their ability to provide a critical overview of specific subjects and their involvement in original work. I shall review the aims of this second volume, and then elaborate on the scope of its con­ tents. The principal aim of the volumes on cancer chemotherapy in the‘ Cancer Treatment and Research‘ series, as stated in the preface to the first volume, is to assemble in a concentrated form selected ingredients of chemothera­ peutic progress. These ingredients are to include concepts in therapeutic strategy, pre-clinical studies, development of major classes of compounds, identificatlon of new directions and of landmarks of clinical progress. Thus we do not foresee overlap with series which provide an yearly update of chemotherapy in an encyclopedic manner, or reviews of cancer chemother­ apy. Unlike those publications, our volumes are not intended to seek a place in shelve
出版日期Book 1985
关键词DNA; cancer treatment; carcinoma; cell; transplantation
版次1
doihttps://doi.org/10.1007/978-1-4613-2563-5
isbn_softcover978-1-4612-9610-2
isbn_ebook978-1-4613-2563-5Series ISSN 0927-3042 Series E-ISSN 2509-8497
issn_series 0927-3042
copyrightMartinus Nijhoff Publishers, Boston 1985
The information of publication is updating

书目名称Experimental and Clinical Progress in Cancer Chemotherapy影响因子(影响力)




书目名称Experimental and Clinical Progress in Cancer Chemotherapy影响因子(影响力)学科排名




书目名称Experimental and Clinical Progress in Cancer Chemotherapy网络公开度




书目名称Experimental and Clinical Progress in Cancer Chemotherapy网络公开度学科排名




书目名称Experimental and Clinical Progress in Cancer Chemotherapy被引频次




书目名称Experimental and Clinical Progress in Cancer Chemotherapy被引频次学科排名




书目名称Experimental and Clinical Progress in Cancer Chemotherapy年度引用




书目名称Experimental and Clinical Progress in Cancer Chemotherapy年度引用学科排名




书目名称Experimental and Clinical Progress in Cancer Chemotherapy读者反馈




书目名称Experimental and Clinical Progress in Cancer Chemotherapy读者反馈学科排名




单选投票, 共有 0 人参与投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 23:02:47 | 显示全部楼层
Chemotherapy in Osteosarcoma: Advances and Controversies,ablished disease. These developments, however, have not been without controversy [10–13]. The latter emerged principally from a comparison of the results of the new investigations with historical controls. This communication will outline the impact of chemotherapy in osteosarcoma and examine the controversial issues.
发表于 2025-3-22 03:24:10 | 显示全部楼层
发表于 2025-3-22 07:41:56 | 显示全部楼层
https://doi.org/10.1007/978-3-642-86867-2enous thiols does not interfere with the immunosuppressive (i.e. myelosuppressive) and carcinostatic properties of CP, which appear to be the consequence of metabolism-dependent formation of the alkylating metabolites of CP, presumably phosphoramide mustard.
发表于 2025-3-22 11:38:17 | 显示全部楼层
发表于 2025-3-22 15:53:03 | 显示全部楼层
0927-3042 odels; drug classes; and clinical settings. Topics were chosen because of their timeliness or probable current impact in cancer treatment. Authors were selected on the basis of their ability to provide a critical overview of specific subjects and their involvement in original work. I shall review th
发表于 2025-3-22 19:08:01 | 显示全部楼层
发表于 2025-3-23 00:50:54 | 显示全部楼层
发表于 2025-3-23 02:55:39 | 显示全部楼层
发表于 2025-3-23 08:16:59 | 显示全部楼层
Book 1985g classes; and clinical settings. Topics were chosen because of their timeliness or probable current impact in cancer treatment. Authors were selected on the basis of their ability to provide a critical overview of specific subjects and their involvement in original work. I shall review the aims of
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-22 03:25
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表